Press Release – For Immediate Release

InQ Biosciences Announces New Board Members

Huntsville, Ala. – InQ Biosciences Corporation, a provider of innovative technologies for

cell growth and research, announced that Michael Chambers and John R. Cooper have been
appointed to the board of directors.

“Michael and John bring successful leadership and deep experience in life science and
technology to the Board. We look forward to applying their spirit of innovation and success
to the growth of InQ Biosciences,” said Dick Reeves, chairman and chief executive officer,
InQ Biosciences.

Michael Chambers, Ph.D. is President and CEO of Swift Biotechnology, an emerging

company targeting development of cancer diagnostics. He actively invests in early-stage
high-growth companies and serves on the board of ProUroCare, a publicly traded company.
Previously, Chambers helped establish InnoRx Pharmaceuticals in 1999, a company
specializing in development of drugs and drug delivery systems for ocular disease. He
served as president and CEO of InnoRx until negotiating its sale and merger into SurModics.

John Cooper is the retired chairman and CEO of publicly traded Avocent Corporation. From
2002 until 2008, he led Avocent through a period of rapid growth to become one of the
largest companies in local and remote IT infrastructure management. From 1996 to 2001,
Mr. Cooper was chief financial officer and senior vice president for finance and
administration, of publicly traded ADTRAN, Inc., a leading global provider of networking and
telecommunications solutions with revenues of $300 million.

InQ Biosciences provides the InQTM Cell Research System, the first fully integrated system
that creates an in vivo-like environment for studying sensitive nerve, brain, and other
human cells for disease research. It is the only cell research instrument that combines a
dynamic software-controlled sample environment with powerful imaging and real-time data
collection. These unique capabilities enable researchers to achieve unprecedented cell
culture control, viability, and visibility that was previously unattainable.

About InQ Biosciences

InQ Biosciences is a provider of innovative technologies for cell growth and research. The
company’s InQ Cell Research System will empower scientists to unlock novel and more
powerful approaches to cell-based discovery. The firm was founded in 2007 with technology
originating from the University of Alabama in Huntsville. Series B financing was completed
in May 2010 and commercial launch of its InQ system is scheduled for the fourth quarter of
2010. For more information, visit www.inqbio.com. Follow InQ Biosciences on Twitter at
@InQbio (http://twitter.com/InQbio).

###

Press contact & photos: Don Goncalves, Tiziani Whitmyre, Inc., 781-793-9380,
dgoncalves@tizinc.com